Bacteriophage-derived depolymerases as antimicrobial synergists: A strategy to overcome resistance
Shuhong Han1,2,3, David H Yang4, Jiayin Shen1,2,3
1National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Abstract:
Upon infection, bacteria form polysaccharides barriers, such as capsular polysaccharide (CPS), exopolysaccharide (EPS) and lipopolysaccharide (LPS). The barrier hinders antibiotic penetration and host immune clearance, exacerbating antimicrobial resistance crisis. Bacteriophages (phages), natural viruses that can specifically infect and kill bacteria, have evolved depolymerase to degrade the polysaccharides. This review evaluates the primary therapeutic value of depolymerases as synergists to existing therapies, systematically detailing their potential to enhance antibiotic efficacy, improve phage therapy, and augment host immunity. We further integrate an evolutionary perspective to analyze likely adaptive responses and potential strategies to eradicate resistance. Finally, the discussion addresses formulation challenges and future prospects for the clinical translation of depolymerase-based synergistic therapies.
Related Concept Videos
Lysogenic Cycle of Bacteriophages
Lytic Cycle of Bacteriophages
DNA Bacteriophages
Antimicrobial Effectiveness
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems


